Levels of regulatory T cells and invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma

Boulassel,Mohamed-Rachid; Al Qarni,Zahra; Burney,Ikram; Khan,Hammad; Al-Zubaidi,Abeer; Al Naamani,Amal; Al-Hinai,Huda; Al-Badi,Amira; Qureshi,Rizwan Nabi; Panjwani,Vinodh; Al Farsi,Khalil

doi:10.3892/mco.2018.1732

Levels of regulatory T cells and invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma

Authors:
- Mohamed-Rachid Boulassel
- Zahra Al Qarni
- Ikram Burney
- Hammad Khan
- Abeer Al-Zubaidi
- Amal Al Naamani
- Huda Al-Hinai
- Amira Al-Badi
- Rizwan Nabi Qureshi
- Vinodh Panjwani
- Khalil Al Farsi
View Affiliations

Affiliations: Department of Allied Health Sciences, Sultan Qaboos University, Muscat 123, Sultanate of Oman, Department of Medicine, Sultan Qaboos University Hospital, College of Medicine and Health Sciences, Muscat 123, Sultanate of Oman, Department of Haematology, Sultan Qaboos University Hospital, College of Medicine and Health Sciences, Muscat 123, Sultanate of Oman
Published online on: October 2, 2018 https://doi.org/10.3892/mco.2018.1732
Pages: 677-682

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to their immunoregulatory properties, several specialized cell subsets, including regulatory T (Treg), invariant natural killer T (iNKT) and regulatory B (Breg) cells, are involved in the pathogenesis of non-Hodgkin lymphoma (NHL). However, the interaction between various cells remains to be elucidated. The aim of the present study was to evaluate the levels of Treg, iNKT and Breg cell subsets and their interrelationships in the peripheral blood (PB) and bone marrow (BM) of patients with B-cell NHL who received rituximab-based regimens and achieved a complete remission. A total of 20 patients and 20 healthy age- and sex-matched controls were prospectively enrolled for investigation of Treg, iNKT and Breg cell subsets in PB and BM by flow cytometry and cell culture. Prior to administration of combination chemotherapy with rituximab, the patients had lower levels of Breg cells and, to a lesser degree, Treg cells, but not iNKT cells, in PB compared with controls. Compartmental differences in the levels of Treg and Breg cell subsets, but not iNKT cells, were observed between PB and BM, suggesting an increase in trafficking through the blood of these regulatory cell subsets to the marrow. Following complete remission, the levels of circulating Treg, iNKT and Breg cell subsets increased. The levels of Treg cells were not significantly associated with iNKT and Breg cell subsets, although negative correlations were observed. Taken together, these results may provide new insights into the potential role of regulatory cell subsets in patients with B-cell NHL. However, whether the observed differences between PB and BM may affect clinical outcomes requires further investigation.

View Figures

View References

1	Sakaguchi S, Miyara M, Costantino CM and Hafler DA: FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 10:490–500. 2010. View Article : Google Scholar : PubMed/NCBI
2	Mauri C and Menon M: Human regulatory B cells in health and disease: Therapeutic potential. J Clin Invest. 127:772–779. 2017. View Article : Google Scholar : PubMed/NCBI
3	Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA and Mauri C: CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 5:173ra232013. View Article : Google Scholar : PubMed/NCBI
4	Oleinika K, Rosser EC, Matei DE, Nistala K, Bosma A, Drozdov I and Mauri C: CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells. Nat Commun. 9:6842018. View Article : Google Scholar : PubMed/NCBI
5	Vomhof-DeKrey EE, Yates J, Hägglöf T, Lanthier P, Amiel E, Veerapen N, Besra GS, Karlsson MC and Leadbetter EA: Cognate interaction with iNKT cells expands IL-10-producing B regulatory cells. Proc Natl Acad Sci USA. 112:12474–12479. 2015. View Article : Google Scholar : PubMed/NCBI
6	Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP and Biragyn A: Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 71:3505–3515. 2011. View Article : Google Scholar : PubMed/NCBI
7	Bodogai M, Lee Chang C, Wejksza K, Lai J, Merino M, Wersto RP, Gress RE, Chan AC, Hesdorffer C and Biragyn A: Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 73:2127–2138. 2013. View Article : Google Scholar : PubMed/NCBI
8	Horikawa M, Minard-Colin V, Matsushita T and Tedder TF: Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest. 121:4268–4280. 2011. View Article : Google Scholar : PubMed/NCBI
9	Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, et al: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016. View Article : Google Scholar : PubMed/NCBI
10	Boulassel MR, Al-Ghonimi M, Al-Balushi B, Al-Naamani A, Al-Qarni Z, Wali Y, Elshinawy M, Al-Shezawi M, Khan H, Nazir H, et al: Regulatory B Cells Are Functionally Impaired in Patients Having Hemophilia A With Inhibitors. Clin Appl Thromb Hemost. 24:618–624. 2018. View Article : Google Scholar : PubMed/NCBI
11	Boulassel MR, Mercier F, Gilmore N and Routy JP: Immunophenotypic patterns of CD8+ T cell subsets expressing CD8α and IL-7Rα in viremic, aviremic and slow progressor HIV-1-infected subjects. Clin Immunol. 124:149–157. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gunduz E, Sermet S and Musmul A: Peripheral blood regulatory T cell levels are correlated with some poor prognostic markers in newly diagnosed lymphoma patients. Cytometry B Clin Cytom. 90:449–454. 2016. View Article : Google Scholar : PubMed/NCBI
13	Lin H, Sun XF, Zhen ZJ, Xia Y, Ling JY, Huang HQ, Xia ZJ and Lin TY: Correlation between peripheral blood CD4+CD25high CD127low regulatory T cell and clinical characteristics of patients with non-Hodgkin's lymphoma. Chin J Cancer. 28:1186–1192. 2009. View Article : Google Scholar
14	Han Y, Wu J, Bi L, Xiong S, Gao S, Yin L, Jiang L, Chen C, Yu K and Zhang S: Malignant B cells induce the conversion of CD4⁺CD25- T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PLoS One. 6:e286492011. View Article : Google Scholar : PubMed/NCBI
15	Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN and Vickers MA: Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood. 111:5359–5370. 2008. View Article : Google Scholar : PubMed/NCBI
16	Cao J, Guo P, Xiao S and Fu X: Relationship of regulatory T cell level in peripheral blood with curative efficacy and prognosis of patients with non-Hodgkin's lymphoma. Int J Clin Exp Pathol. 9:11876–11882. 2016.
17	Chang C, Wu SY, Kang YW, Lin KP, Chen TY, Medeiros LJ and Chang KC: High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma. Am J Clin Pathol. 144:935–944. 2015. View Article : Google Scholar : PubMed/NCBI
18	Mohr A, Malhotra R, Mayer G, Gorochov G and Miyara M: Human FOXP3+ T regulatory cell heterogeneity. Clin Transl Immunology. 7:e10052018. View Article : Google Scholar : PubMed/NCBI
19	Wang J and Ke XY: The four types of Tregs in malignant lymphomas. J Hematol Oncol. 4:502011. View Article : Google Scholar : PubMed/NCBI
20	Qiu H, Li J, Feng Z, Yuan J, Lu J, Hu X, Gao L, Lv S, Yang J and Chen L: CD19(+) CD20(−) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission. Clin Exp Pharmacol Physiol. 43:795–801. 2016. View Article : Google Scholar : PubMed/NCBI
21	Pierini A, Nishikii H, Baker J, Kimura T, Kwon HS, Pan Y, Chen Y, Alvarez M, Strober W, Velardi A, et al: Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nat Commun. 8:150682017. View Article : Google Scholar : PubMed/NCBI
22	Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, Wang G and Zou W: Bone marrow and the control of immunity. Cell Mol Immunol. 9:11–19. 2012. View Article : Google Scholar : PubMed/NCBI
23	Metelitsa LS: Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol. 140:119–129. 2011. View Article : Google Scholar : PubMed/NCBI
24	Yoneda K, Morii T, Nieda M, Tsukaguchi N, Amano I, Tanaka H, Yagi H, Narita N and Kimura H: The peripheral blood Vα24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk Res. 29:147–152. 2005. View Article : Google Scholar : PubMed/NCBI
25	Hus I, Bojarska-Junak A, Kamińska M, Dobrzyńska-Rutkowska A, Szatan K, Szymczyk A, Kukiełka-Budny B, Szczepanek D and Roliński J: Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin's lymphoma. Oncol Lett. 14:7957–7964. 2017.PubMed/NCBI
26	Yan-Li L, Kang-Sheng G, Yue-Yin P, Yang J and Zhi-Min Z: The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leuk Res. 38:323–328. 2014. View Article : Google Scholar : PubMed/NCBI